May 2011
Worldwide Biotech;May2011, Vol. 23 Issue 5, p7
Trade Publication
The article reports on Laboratoires Thea's acquisition of products from Novartis in the European Economic Area (EEA), Canada, Mexico and Turkey. The deal is seen to improve the product line-up of the company especially in places it is not current active. Jean-Frederic Chibret, Laboratories Thea president, said that the acquisition can help them improve their sales and also the sales of the product line they bought from Novartis. The company has also launched the ABAK technology, which is the first preservative-free multi-dose eye drop system.


Related Articles

  • In Brief.  // Ophthalmology Times;10/15/2010, Vol. 35 Issue 20, p7 

    The article reports on the acquisition of a mydriatic ophthalmic insert (Mydriasert) from Carl Zeiss Meditec AG by Laboratoires Thea for dilate fundus examination and cataract surgery.

  • New company for pharmaceuticals.  // Optometry Today;8/15/2008, Vol. 48 Issue 16, p20 

    The article focuses on Spectrum Théa Pharmaceuticals, a recently launched company in Great Britain and Ireland which offers ophthalmic products to optometrists, ophthalmologists, nursing staff and pharmacists. It specialises in products for dry eye and blepharitis. The company was formed...

  • Novartis Unit Winks at Consumers With Eye-Catching Ads for Drops. Bittar, Christine // Brandweek;2/24/2003, Vol. 44 Issue 8, p4 

    Reports on the advertising campaign of Novartis for its Zaditor or Z-Drops brand of prescription eye drops. Concept of the campaign; Mediums that will be used on the campaign.

  • Combination agents target early, late stages of allergy. Groves, Nancy // Ophthalmology Times;5/1/2003, Vol. 28 Issue 9, p20 

    Focuses on Zaditor, a ketotifen fumarate ophthalmic solution from Novartis AG for the treatment of seasonal and year-round ocular allergies. Active ingredient; Mechanism of action; Ability to target various stages of the allergy.

  • COMPANY SPOTLIGHT - Novartis AG.  // PharmaWatch: CNS;July 2003, Vol. 2 Issue 7, p33 

    Focuses on the business performance of Novartis AG in Switzerland. Analysis on the revenue growth of the firm; Number of distributors; Expansion on the product lines of the company.

  • Lonza to Co-Develop Novartis Biologics Pipeline. Ramesh, Deepti // Chemical Week;7/21/2008, Vol. 170 Issue 22, p25 

    The article reports that Lonza has entered into a long-term partnership with Novartis to jointly develop and manufacture Novartis' biologics product line. Under the deal, Lonza will provide services from its research and development (R&D) center at Slough, England using its GS Gene Expression...

  • Leading Indicators.  // Pharmaceutical Executive;Mar2005, Vol. 25 Issue 3, p21 

    Reports on developments involving companies in the pharmaceutical industry in the U.S. Lead of Novartis AG, the fourth largest drug maker in the world, over Teva Pharmaceuticals, a drug maker, in terms of market share in the global generics market; Acquisition of Daiichi, a pharmaceutical...

  • Other News To Note.  // BioWorld Today;4/3/2012, Vol. 23 Issue 64, p2 

    This section offers news briefs on the biopharmaceutical sector. A milestone payment was received by Ablynx NV from partner Novartis AG as a result of the approval of an investigational new drug application for a Phase I trial of Nanobody. There is a plan by GlaxoSmithKline PLC to invest in...

  • Novartis: higher bid to secure Chiron deal.  // PharmaWatch: Biotechnology;May2006, Vol. 5 Issue 5, p22 

    The article reports that Novartis AG has increased its offer to acquire Chiron Corp., one the world's leading vaccine producers, in an effort to expedite the completion of the acquisition deal. The new $5.3 billion offer showed a $3 increase per share to the 56% remaining shares that Novartis...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics